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Junctional adhesion molecule-A (JAM-A, also known as F11R), a member of the immunoglobulin superfamily, is 
located in the tight junctions of epithelial and endothelial cells 
but also expressed by leukocytes and CD34+ cells, and exerts a 
wide variety of functions in cell polarity1 and barrier function 
via homophilic interactions,2 stem cell adhesion and differen-
tiation,3 leukocyte trafficking, and recruitment.3–6 In particular, 
JAM-A mediates leukocyte adhesion and transmigration via 
heterophilic interactions with the αLβ2 integrin LFA-1.7–10 
Moreover, dendritic cell trafficking to the lymph nodes was 
increased in mice with somatic but not endothelial JAM-A 
deficiency, indicating a specific role in dendritic cell migra-
tion.11 Additional findings revealed a crucial role of JAM-A 
on leukocytes in promoting de-adhesion.12 In the absence of 
JAM-A, the directional motility of neutrophils was impaired, 
leading to incomplete transmigration with neutrophils being 
stuck between the endothelial cell layer and the basement 
membrane.12 Whereas JAM-A on neutrophils promotes che-
motaxis by regulating integrin internalization and recycling,13 
endothelial JAM-A has been implicated in mediating stimu-
lus-specific neutrophil transmigration.14 Upon costimulation 
with tumor necrosis factor (TNF)-α and interferon (IFN)-γ, 
endothelial JAM-A is redistributed to the luminal surface15,16 
and specifically to the site of leukocyte transmigration as part 
of lateral border recycling compartments.17
Clinical Perspective on p 76
Compelling evidence has emerged to indicate that JAM-A-
mediated leukocyte transmigration plays an important role in 
inflammatory disease. For example, JAM-A–deficient mice 
displayed reduced leukocyte infiltration in models of perito-
nitis, hepatic and myocardial ischemia-reperfusion injury,12,18 
and in acute lung injury.19 In models of vascular disease, 
somatic JAM-A deficiency was shown to protect against 
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neointimal hyperplasia after wire-injury of the carotid artery 
in hyperlipidemic mice.20 Accordingly, increased levels of 
JAM-A transcripts and protein have been demonstrated in 
human plaque biopsies and in plaque-prone aortas of mice.21 
The expression of JAM-A on inflamed and early atheroscle-
rotic endothelium has been implicated in the recruitment of 
mononuclear cells through an inhibition with soluble JAM-A, 
suggesting a functional involvement in atherogenesis.5
Despite being strategically positioned at junctional entry 
ports of arterial endothelium, less is known about the cell-spe-
cific contributions and net effect of JAM-A in directing mono-
nuclear cell migration during atherogenic recruitment and 
lesion formation. To dissect the functions of JAM-A in athero-
sclerosis, we used apolipoprotein E–deficient (Apoe–/–) mice 
with a somatic or endothelial cell-specific deficiency in JAM-A 
and bone marrow (BM) chimeras with JAM-A–deficient leu-
kocytes. Our data show that endothelial JAM-A promotes 
lesion formation by integrating effects of hyperlipidemia and 
disturbed flow, which result in its upregulation, redistribution, 
and subsequent function in promoting mononuclear cell influx 
into the artery wall, while limiting reverse transmigration. In 
contrast, leukocytic JAM-A is required for monocyte de-adhe-
sion and complete transmigration, thereby preventing vascular 
damage and protecting against atherosclerosis.
Methods
Mouse Models of JAM-A–Deficiency and  
Plaque Formation
Somatic JAM-A–/–Apoe–/– were backcrossed for >10 generations 
into a C57Bl/6 background.20 Congenic Apoe–/– mice were used as 
controls. Chimeric mice with a leukocytic JAM-A deficiency were 
obtained by reconstituting Apoe–/– recipients with JAM-A–/–Apoe–/– or 
JAM-A+/+Apoe–/– BM.22
A genetic reduction of endothelial JAM-A was achieved by 
crossing Apoe–/– mice with a loxP-flanked (floxed) JAM-A gene 
(JAM-Afl/fl) with VeCad-CreERT2Apoe–/– mice to obtain VeCad-
CreERT2JAM-Afl/flApoe–/– mice (C57Bl/6).23 At an age of 3 weeks, 
5 daily intraperitoneal injections of the estradiol analog tamoxifen 
(0.04 mg/g) dissolved in miglyol 810 were administered to VeCad-
CreERT2–positive or VeCad-CreERT2–negative animals to obtain 
eJAM-A–/–Apoe–/– or eJAM-A+/+Apoe–/– mice, respectively. After 4–6 
weeks, genetic depletion of JAM-A was confirmed by FACS analy-
sis, resulting in ≈50% less endothelial JAM-A levels with no differ-
ence in leukocytic JAM-A levels compared with control mice. We 
chose a mouse model with an inducible endothelium-specific Cre-
recombinase, because constitutive expression of Cre-recombinase 
under the control of endothelium-specific promoters (e.g. Tie2/Tek, 
VE-cadherin) can lead to deletion of the floxed gene in hematopoi-
etic cells.24,25
Plaque formation was induced in female littermates (aged 6–8 
weeks, n=10–13) by feeding a high-fat diet (HFD, 21% fat, 0.15% 
cholesterol) for 12 weeks or by partial ligation of the carotid artery, 
resulting in altered shear stress attributable to reduced and partially 
retrograde blood flow.26 In brief, Apoe–/– mice (n=5) were anesthetized 
with ketamine (80 mg/kg) and xylazine (10 mg/kg), and left external 
and internal carotid, and occipital artery were ligated with 6-0 silk 
sutures, leaving only superior thyroid artery open. Animal experi-
ments were approved by local authorities and complied with German 
animal protection law (LANUV NRW, Recklinghausen, Germany).
Quantification and Immunohistochemical Analysis 
of Atherosclerosis
Plaques and lipid depositions in aortic roots and in thoracoabdominal 
aortas were visualized by Elastica van Gieson or Oil-red-O staining, 
respectively, and quantified by computerized image analysis.22 The 
relative content of macrophages and CD3+ T-cells was determined 
by staining with anti–Mac-2 and anti-CD3, and detection with FITC- 
and Cy3-conjugated antibodies. Nuclei were visualized with DAPI. 
Necrotic core areas were quantified in DAPI-stained slices of aortic 
roots. Stages of atherosclerotic lesions were determined by evaluation 
of Elastica van Gieson–stained aortic roots.27
Stimulation of Endothelial Cells Under Static or 
Flow Conditions
Human aortic endothelial cells (HAoECs) without genetic modi-
fication, and JAM-A+/+ Apoe–/– or JAM-A–/–Apoe–/– SV40-large T 
antigen-immortalized mouse ECs (SVECs) were grown on collage-
nized glass slides or Bioflux 48-well plates, respectively. HAoECs 
were treated with low-density lipoprotein (LDL), oxidized LDL 
(oxLDL; both 10 µg/ml, 16 h), TNF-α and IFN-γ (10 ng/ml and 20 
ng/ml, 4 h, respectively), or oxLDL plus JAM-A.Fc (10 µg/ml, 15 
min). Mouse ECs were activated for at least 4 h with TNF-α (25 ng/
ml). For culture under flow conditions, HAoECs were transferred 
to 0.4-µm µ-slides (ibidi, Martinsried, Germany). Cell culture was 
continued under static or flow conditions for 48 h, while shear 
stress was gradually increased to 5 or 20 dyn/cm2 using an ibidi 
pump system.
In Vitro, Ex Vivo, and In Vivo Monocyte Adhesion 
and Transmigration Assays
CD14+ human monocytes and CD115+ mouse monocytes were 
freshly isolated from human blood or mouse spleens using 
Monocyte Isolation Kit II or the CD115 mouse MicroBead Kit and 
were applied on endothelial cells under shear stress (1.5 dyn/cm2) 
in a laminar flow chamber for up to 10 min and flushed with assay 
medium for 30 min during time-lapse recordings. Monocytes show-
ing complete, reverse, and incomplete transmigration were counted 
relative to adherent or total transmigrated monocytes. Human studies 
were approved by the institutional review board and informed con-
sent was given by the subjects.
For de-adhesion assays, JAM-A+/+ and JAM-A–/– CD115+ mono-
cytes were allowed to adhere on TNF-α–stimulated SVEC mono-
layers or coated intercellular adhesion molecule-1.Fc protein at 0.75 
dyn/cm2 in µ-slides0.4. Shear stress was gradually increased to 11.5 
dyn/cm2 and monocytes remaining adherent were counted.
Carotid arteries of Apoe–/– mice were explanted, mounted, pressur-
ized at 80 mm Hg, and incubated with FITC-coupled CD31 antibody 
(5 µg/ml). After stimulation of carotid arteries with TNF-α (10 ng/
ml, 3 h), Rhodamine B–stained (1 µg/ml) primary CD115+ mono-
cytes with and without JAM-A deficiency (6×105 cells) were perfused 
in the mounted and pressurized vessel at 0.4 ml/min and visualized 
using 2-photon laser scanning microscopy (TPLSM).
The right carotid arteries of eJAM-A–/– and eJAM-A+/+ mice were 
challenged with interleukin-1β (2 µg/ml) carried by a slowly degrad-
ing periarterial pluronic gel for 24 h. In addition, Alexa Fluor (AF) 
568-coupled anti-CD115 antibody (5 µg/mouse) was administered 
intravenously. On the next day, anaesthetized mice were injected 
intravenously with anti-CD31 FITC-coupled antibody (35 µg/mouse 
total) and prepared for in vivo TPLSM by surgically exposing the 
common carotid artery.28
TPLSM of the Carotid Artery In Vitro and In Vivo
Imaging was performed using a resonant scanning Leica SP5MP 
(in vivo) or an Olympus FV1000MP with a pulsed Ti:Sapphire 
Laser tuned at 800 nm and a 20×NA1.00 (Leica) or a 25×NA1.05 
(Olympus) water immersion objective.28
Quantification of Immunofluorescence
HAoECs cultured under flow conditions were stained with an anti–
JAM-A antibody (10 µg/ml, 2 h, clone M.Ab.F11) followed by 
secondary antibody staining (anti-mouse immunoglobulin Alexa 
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clone 5.6E). Slides were imaged using a High-Content Imager (BD 
Pathway 855) with a 20× objective. Per slide, 10 images were taken. 
Using AttoVision-software, cells were segmented and fluorescence 
intensity per cell was determined.
Fluorescent Bead Assay
HAoECs were incubated with fluorescent microbeads (≈1 µm diam-
eter) coupled to JAM-A antibodies (clone 246) for 30 min. Nuclei 
were stained with HOECHST 33342. After washing, bright field and 
fluorescent images were recorded. Bead numbers were related to 
nuclei count and normalized to binding of immunoglobulin-coupled 
control beads.
MiR-145 Transfection of HAoECs
HAoECs grown to 80% confluence were transfected with 
microRNA (miR)-145-3p or miR-145-5p mimics (75 pmol/L) 
using Lipofectamine 2000. Quantitative (q)PCR analysis of JAM-A 
mRNA and miR-145 levels was performed after 24 h using estab-
lished protocols.5,29
Statistical Analysis
Statistical analysis was performed using Prism 6.0 (GraphPad 
Software). Means were compared between 2 groups by 2-tailed, 
unpaired, or paired Student t test, without or with Welch correc-
tion or among more than 2 groups by 1-way ANOVA with Tukey or 
Bonferroni post test or Kruskal-Wallis test with Dunn post test, as 
indicated. Differences with P<0.05 were considered as statistically 
significant.
For more detailed information please see the online-only Data 
Supplement.
Results
Deficiency in Endothelial JAM-A Protects  
Against Atherosclerosis
The inhibition of mononuclear cell recruitment by soluble 
JAM-A has implicated JAM-A in atherogenesis,5 however, 
owing to its pleiotropic functions the overall and cell-specific 
effects of JAM-A have remained elusive. Notably, somatic 
JAM-A deletion did not significantly affect atherosclerotic 
lesion area in the thoracoabdominal aorta and the aortic root 
of Apoe–/– mice fed a HFD for 12 weeks (Figure 1A and 
1B). In contrast, reconstitution of Apoe–/– mice with JAM-
A–/–Apoe–/– BM (leuJAM-A–/–Apoe–/–) enhanced diet-induced 
lesion area in the thoracoabdominal aorta but not in the aortic 
root, as compared with controls carrying JAM-A+/+Apoe–/– BM 
(leuJAM-A+/+Apoe–/–), indicating an atheroprotective function 
of JAM-A on BM-derived leukocytes (Figure 1C and 1D). 
In turn, genetic deficiency in endothelial JAM-A reduced 
the diet-induced lesion area in the thoracoabdominal aorta 
and aortic root of tamoxifen-treated VeCad-CreERT2JAM-
Afl/flApoe–/– (eJAM-A–/–Apoe–/–) mice, as compared with their 
Cre– (eJAM-A+/+Apoe–/–) littermates (Figure 1E–1H), demon-
strating a remarkable role of JAM-A on endothelial cells in 
promoting atherosclerosis.
Endothelial JAM-A Deficiency Reduces  
Lesional Infiltration
Immunohistochemistry in the aortic root revealed that the 
lesional content of Mac-2+ macrophages did not differ in 
somatic JAM-A–/–Apoe–/– mice versus JAM-A+/+Apoe–/– con-
trols (Figure 2A). As compared with control chimeras, 
JAM-A deficiency in BM-derived cells reduced macro-
phage content (Figure 2B). Likewise, deficiency in endo-
thelial JAM-A markedly decreased macrophage content, as 
compared with controls with intact JAM-A (Figure 2C and 
2D). The infiltration with CD3+ T-cells characterizing early 
lesion stages was unaffected by somatic deletion of JAM-A 
but markedly reduced in mice with JAM-A–deficient 
leukocytes or with an endothelial deficiency in JAM-A 
(Figure 2E–2G). As a hallmark for advanced lesions, 
necrotic core size was unaltered by somatic deletion of 
JAM-A, higher in mice with JAM-A–deficient BM-derived 
cells, indicative of increased macrophage turnover, and 
considerably reduced by endothelial deficiency in JAM-A 
(Figure 2H–2J). To evaluate the rate of lesion development 
in these mice, we performed a phenotypic classification.27 
Whereas JAM-A–/–Apoe–/– and leuJAM-A–/–Apoe–/– mice 
developed lesions that were mainly in an advanced stage, 
eJAM-A–/–Apoe–/– mice almost exclusively bore lesions 
in initial or intermediate stages, displaying an increase in 
early lesion stages, as compared with controls (Figure 2K). 
Whereas the preponderance of advanced lesions in chimeric 
mice is likely related to irradiation, a higher proportion of 
Figure 1. Cell-specific role of junctional adhesion molecule 
(JAM)-A deficiency in atherosclerosis. JAM-A+/+Apoe–/– and 
JAM-A–/–Apoe–/– mice (A and B), leuJAM-A+/+Apoe–/– and 
leuJAM-A–/–Apoe–/– mice (C and D), eJAM-A+/+Apoe–/– and eJAM-
A–/–Apoe–/– mice (E and F) were fed a high-fat diet for 12 weeks. 
Atherosclerotic lesions were quantified in the thoraco-abdominal 
aorta after Oil-red-O staining (A, C, and E) and in the aortic root 
after Elastica van Gieson staining (B, D, and F). Representative 
images depict the thoracoabdominal aortas (G) and aortic roots 
of eJAM-A+/+Apoe–/– and eJAM-A–/–Apoe–/– mice (H). Scale bar, 
200 µm. Data represent mean±SEM (n=10–13), and all P values 







































































































































































































 http://ahajournals.org by on Septem
ber 21, 2021
Schmitt et al  Cell Type–Specific Role of JAM-A in Atherogenesis  69
less advanced lesion stages in the eJAM-Afl/fl lines could be 
attributable to tamoxifen treatment or residual differences 
in genetic background. Taken together, cell type–specific 
effects of leukocyte and endothelial JAM-A deficiency dif-
ferentially modulate the inflammatory phenotype and stage 
of atherosclerotic plaques.
Role of Endothelial JAM-A in Arterial  
Leukocyte Recruitment
We used in vivo, ex vivo and in vitro adhesion and trans-
migration assays to mechanistically evaluate the role of 
endothelial and leukocytic JAM-A in arterial monocyte 
recruitment. Indeed, we found a lower number of wild-type 
CD115+ monocytes that had crossed the endothelial layer 
of carotid arteries in eJAM-A–/– mice after treatment with 
interleukin-1β, as compared with eJAM-A+/+ controls, both 
during in vivo recording (Figure 3A) and in situ after sac-
rifice (Figure 3B). Accordingly, the adhesion of wild-type 
monocytes to JAM-A-deficient endothelial monolayers stim-
ulated with TNF-α/IFN-γ was unaltered but their transmi-
gration underneath JAM-A-deficient endothelial monolayers 
was markedly reduced, compared with JAM-A-bearing 
endothelial cells (Figure 3C and 3D). The decreased trans-
migration of monocytes across JAM-A–deficient endothelial 
cells might also be explained by an increase in reverse trans-
migration, which was only observed when JAM-A+/+ leu-
kocytes transmigrated across JAM-A–deficient endothelial 
cells (Figure 3E).
Leukocytic JAM-A Deficiency Impairs De-Adhesion 
and Endothelial Barrier Function
As compared with wild-type monocytes, JAM-A–/– mouse 
monocytes showed a marked increase in firm adhesion to ex 
vivo perfused wild-type carotid arteries (Figure 3G) and to 
JAM-A+/+ endothelial cells in a recruitment assay under flow 
conditions in vitro (Figure 3C). This was accompanied by 
reduced transmigration of JAM-A–/– monocytes (Figure 3D), 
which may be attributable to a defect in de-adhesion.12 JAM-A–/– 
monocytes showed a higher rate of incomplete transmigration 
(defined as cells that had entered endothelial junctions without 
exiting, thus being entrapped) across both JAM-A–expressing 
or JAM-A–deficient endothelial cells (Figure 3F), explaining 
the overall decrease in complete transmigration (Figure 3D). 
To confirm defective de-adhesion of JAM-A–/– monocytes, we 
performed assays under variable flow conditions. Compared 
with JAM-A+/+ controls, adherent JAM-A–/– monocytes were 
more resistant to shear stress and detachment induced by 
gradually increasing flow rates both on stimulated SVEC 
monolayers (Figure 3H) and the β2 integrin ligand intercel-
lular adhesion molecule-1.Fc (Figure 3I). This clearly indi-
cates that de-adhesion was impaired in  JAM-A–/– monocytes 
and that this effect was likely mediated by increased activity 
of β2 integrins.
Because compromised endothelial integrity is a hallmark 
of early atherosclerosis,30 we investigated the permeability 
of the carotid artery wall of Apoe–/– mice deficient in leuko-
cytic and endothelial JAM-A fed with or without HFD for 6 
Figure 2. Phenotype of atherosclerotic lesions in junctional adhesion molecule (JAM)-A–deficient mice. The relative content of Mac-2+ 
macrophages (A–D) and CD3+ T cells (E–G) in aortic root lesions was analyzed by quantitative immunofluorescence. Representative 
images of Mac-2–stained aortic roots isolated from eJAM-A+/+Apoe–/– and eJAM-A–/–Apoe–/– mice are shown (D). Scale bar, 200 µm. 
Necrotic core size in aortic root lesions was quantified after DAPI staining (H–J). JAM-A+/+Apoe–/– and JAM-A–/–Apoe–/– mice (A, E, and H), 
leuJAM-A+/+Apoe–/– and leuJAM-A–/–Apoe–/– mice (B, F, and I), and eJAM-A+/+Apoe–/– and eJAM-A–/–Apoe–/– mice (C, D, G, and J) were 
fed a high-fat diet for 12 weeks. The lesions were phenotypically characterized according to the stage (K). FCA indicates fibrous cap 
atheroma; IX, intimal xanthoma; and PIT, pathologic intimal thickening. Data represent mean±SEM (n=10–13), and all P values were 




















































































































































































 http://ahajournals.org by on Septem
ber 21, 2021
70  Circulation  January 7, 2014
weeks. As assessed by ex vivo TPLSM, the uptake of fluo-
rescent dextran into the arterial media was not affected by 
HFD or endothelial JAM-A deficiency but increased by hista-
mine-treatment or leukocytic JAM-A–deficiency (Figure 3J) 
Altered vascular permeability in leuJAM-A–/–Apoe–/– mice 
may reflect the damage inflicted by impaired de-adhesion or 
transmigration of leuJAM-A–/– leukocytes and may explain 
increased lesion formation.
Focal Redistribution of Endothelial JAM-A in 
Lesion-Prone Areas
Analysis of atherosclerotic arteries and plaque tissue revealed 
an increase in JAM-A expression.5,21 We used ex vivo 2-pho-
ton laser scanning microscopy (TPLSM) in unfixed and intact 
carotid arteries of Apoe–/– mice to label JAM-A and to deter-
mine its distribution in plaque-prone vessels as a potential 
mechanism underlying atherogenic leukocyte recruitment 
(Figure I in the online-only Data Supplement). The undis-
eased common part of the carotid artery explanted from 1 
year-old Apoe–/– mice on normal chow showed an orga-
nized mesh-like junctional pattern of JAM-A expression in 
luminal endothelial cells (Figure 4A, left and Movie I in the 
online-only Data Supplement). In contrast, segments near 
the bifurcation, which are prone to lesion formation owing 
to disturbed flow, displayed an apico-luminal redistribution 
and focal concentration of JAM-A away from endothelial 
cell junctions (Figure 4A, middle and right). The middle 
panel shows the transition zone between undiseased seg-
ments with a normal junctional JAM-A pattern (left part) and 
focal enrichment of JAM-A in the shoulder region of a lesion 
(right part). To assess the propensity of JAM-A for early focal 
redistribution during lesion formation, we performed costain-
ing with PECAM-1 (CD31) as another junctional protein 
expressed in endothelial cells (Figure 4B and Figure II in the 
online-only Data Supplement). In carotid arteries of Apoe–/– 
mice fed a HFD for 6 weeks, typical examples of costain-
ing for JAM-A and CD31 in the undiseased common part 
and the plaque-prone areas near the bifurcation are shown 
(Figure 4B, left and middle). Using image analysis, we deter-
mined the pseudo-overlap of JAM-A and CD31 expression 
in undiseased areas for normalization (Figure 4B, right). The 
bifurcation prone to nascent atherosclerotic lesion formation 
Figure 3. Cell-specific effects of junctional adhesion molecule (JAM)-A on transmigration and permeability. A and B, Numbers of 
CD115+ cells located in the vessel wall of common carotid arteries after incubation with interleukin (IL)-1β in a perivascular pluronic gel 
for 24 h were analyzed by in vivo (A) and post mortem in situ (B) 2-photon laser scanning microscopy (TPLSM) in eJAM-A+/+ (n=3) and 
eJAM-A–/– mice (n=7–9). Representative images depict CD115+ monocytes (red; inset shows magnification) migrated into sub-endothelial 
regions, CD31+ endothelium and elastin autofluorescence in green (B, right). Scale bar, 40 µm. C–F, Stable adhesion (C) completed (D), 
reverse (E), and incomplete (F) transendothelial migration of leuJAM-A+/+ or leuJAM-A–/– monocytes perfused on tumor necrosis factor 
(TNF)-α/interferon (IFN)-γ–treated eJAM-A+/+ (black bars) or eJAM-A–/– endothelial cells (grey bars) at 1.5 dyn/cm2 was analyzed by video 
microscopy (n=3–5). G, Adhesion of primary JAM-A+/+Apoe–/– (n=6) and JAM-A–/–Apoe–/– (n=7) CD115+ mouse monocytes was determined 
using TPLSM after ex vivo perfusion of TNF-α–activated carotid arteries (JAM-A+/+Apoe–/–) pressurized at 80 mm Hg. H and I, De-adhesion 
of primary JAM-A+/+ and JAM-A–/–CD115+ mouse monocytes was assessed by detachment of adherent cells at gradually increasing flow 
rates on TNF-α–activated SV40-large T antigen-immortalized mouse EC (SVEC) monolayers (H) or intercellular adhesion molecule-1.Fc 
(I; n=12 each). J, Permeability was assessed by extravasation of 70-kDa FITC-labeled dextran using 2-photon laser scanning microscopy 
(TPLSM) in carotid arteries ex vivo with or without (ctrl) histamine-treatment or after 6 weeks of high-fat diet in Apoe–/– mice (open bars), 
with or without deficiency of endothelial (n=5, grey bars) or leukocyte (n=5, black bars) JAM-A. Data represent mean±SEM, and P values 
were calculated by 1-way ANOVA with Bonferroni (C–F) or Tukey (H–J) multiple comparison test or 2-tailed t test (A, B, G–I).
eJAM-A eJAM-A−/−
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revealed a decrease in junctional colocalization of JAM-A 
and CD31 (72.8±8.4% of control, n=5, P<0.05), implying a 
preferential redistribution of JAM-A.
Oxidized LDL Increases Functional  
JAM-A Expression
To elucidate whether the focal accumulations of endothelial 
JAM-A in atherosclerotic lesions are caused by redistribu-
tion or increased de novo synthesis, we performed JAM-A 
antibody-coupled fluorescent bead assays, real-time PCR, and 
Western blot analysis. Similar to costimulation with TNF-α 
and IFN-γ, treatment with oxLDL but not with native LDL 
increased specific surface binding of anti-JAM-A micro-
beads to aortic endothelial cell monolayers (Figure 5A and 
5B). Blocking de novo protein synthesis with cycloheximide 
partially yet nonsignificantly reduced JAM-A surface levels, 
suggesting that both increased expression and redistribu-
tion contributed to the up-regulation of endothelial surface 
 JAM-A. Treatment with oxLDL but not native LDL or TNF-
α, dose-dependently increased JAM-A transcript and protein 
expression in HAoECs, reaching a plateau at 2.5 µg/ml of 
oxLDL (Figure 5C). To link JAM-A expression to atherogenic 
recruitment, we performed a transmigration assay using clas-
sical CD14+ monocytes and HAoECs under shear flow con-
ditions (Figure 5D). Similar to costimulation with TNF-α/
IFN-γ, treatment with oxLDL but not native LDL caused an 
increase in monocyte transmigration. Notably, blocking endo-
thelial JAM-A with soluble JAM-A.Fc reduced the oxLDL-
induced increase in transmigration to levels seen in untreated 
HAoECs, indicating that the effect of oxLDL on transmigra-
tion is mediated by JAM-A.
The Expression and Localization of JAM-A Is 
Governed by Shear Flow and miR145
Because the increased susceptibility to lesion formation 
in areas near bifurcations or branching points is related to 
altered flow conditions (eg, low or oscillatory flow), we tested 
whether such aberrant flow conditions as induced by partial 
ligation of the carotid artery of Apoe–/– mice affects the local-
ization of JAM-A. Indeed, costaining for JAM-A and CD31 
revealed a discontinuous pattern of JAM-A and redistribution 
from the junctions in the common part of partially ligated 
carotid arteries, as seen in the bifurcation of mice with estab-
lished lesions (Figure 6A and Figure II in the online-only 
Data Supplement). The redistribution of JAM-A was evident 
both in the common part and in the bifurcation, as early as 
2 weeks after ligation (Figure 6A). The pseudo-overlap of 
JAM-A with CD31 was markedly reduced in carotid arteries 
after 2 weeks and this reduction sustained for at least 8 weeks 
after partial ligation (Figure 6B), indicating that JAM-A is 
preferentially redistributed from its junctional expression 
pattern under conditions of disturbed flow. Conversely, the 
control of JAM-A might be linked to atheroprotective lami-
nar flow conditions. Hence, we assessed JAM-A expression 
in HAoECs cultured under static or flow conditions, reveal-
ing an inverse correlation of JAM-A expression with laminar 
shear flow (Figure 6C and 6D). To correlate this effect with 
a JAM-A–dependent local predilection for atherosclerosis, 
Figure 4. Arterial localization of junctional 
adhesion molecule (JAM)-A during 
atherogenesis. A, Visualization of JAM-A 
(green) and collagen (blue, SHG) in an 
explanted carotid artery of a 1-year-old 
Apoe–/– mouse fed normal chow. An 
organized junctional pattern of JAM-A 
staining is evident in the healthy part of 
the carotid artery (left), which changes into 
a focally enriched pattern in the shoulder 
(middle) and core (right) regions of the 
plaque. Images are total projections of 
z-stacks. A schematic drawing (lower 
part) depicts where images were taken. 
Scale bar, 40 µm. B, Costaining (left and 
middle) and semiquantitative analysis 
(right) of CD31 (red) and JAM-A (green) 
in the carotid artery of an Apoe–/– mouse 
fed a high-fat diet for 7 weeks revealed a 
decreased JAM-A/CD31 pseudo-overlap 
in the endothelial junctions at the diseased 
bifurcation, compared with the common 
part. Scale bar, 40 µm. Data represents 
mean±SEM (n=5), and P value was 
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in vivo analysis confirmed that the reduction of atheroscle-
rotic lesion formation in the descending aorta and the aortic 
arch between eJAM-A+/+Apoe–/– and eJAM-A–/–Apoe–/– mice 
was more prominent at regions of low/oscillatory shear stress 
(eg, in the inner curvature of the arch or the descending aorta 
with branching points), as compared with regions with high/
laminar shear flow (eg, the outer curvature of the arch and the 
abdominal aorta; Figure 6E and 6F).
Recent evidence has linked the expression of miR-145 in 
endothelial cells under shear flow conditions to the mechano-
sensitive transcription factor Krüppel-like factor 2.31,32 Indeed, 
culture of HAoECs under shear flow conditions increased the 
expression of miR-145, as compared with static conditions 
(Figure 6G). Notably, an analysis of miR target sequences 
revealed that the gene of JAM-A harbors at least 2 seed 
sequences for miR-145-3p and miR-145-5p (see Figure III 
in the online-only Data Supplement). To investigate whether 
JAM-A expression is regulated by a miR-145-dependent 
mechanism, we transfected HAoECs with miR-145-3p and 
miR-145-5p mimics. Notably, both the miR-145-3p and miR-
145-5p strands reduced the copy number of JAM-A mRNA in 
HAoECs (Figure 6H). These findings suggest that miR-145 
is a flow-dependent regulator of JAM-A expression, which 
may protect against plaque formation by attenuating JAM-A 
mRNA levels under flow conditions. Taken together, endo-
thelial JAM-A levels might serve to functionally integrate 
atherogenic risk factors, such as modified LDL and disturbed 
flow conditions.
Discussion
Here we have unraveled the cell-specific effects and mecha-
nisms exerted by JAM-A in diet-induced atherosclerosis, 
and the overall and context-dependent consequence of its 
genetic deficiency. Previous studies have reported differen-
tial or even contradictory effects of somatic and endothelial 
JAM-A deficiency in various models of tissue injury and 
inflammation.14,17,33,34 This apparent inconsistency may be 
attributable to the use of heterogeneous models affecting 
different vascular beds. We used diet-induced atheroscle-
rotic lesion formation and arterial inflammation in Apoe–/– 
mice and found that endothelial JAM-A promoted lesion 
formation and mononuclear cell infiltration. This effect was 
mediated by an elevated accessibility of JAM-A (through 
upregulation and redistribution) and its function in guiding 
monocyte recruitment, which was stimulated under athero-
genic conditions. The expression and luminal enrichment of 
JAM-A was exacerbated by disturbed flow conditions (eg, 
reduced shear flow), as encountered at predilection sites, 
whereas laminar shear flow induced miR-145 to repress 
JAM-A expression, in a mechanism that may contribute 
to limiting the susceptibility to atherosclerosis. Targeting 
endothelial JAM-A may thus serve as a feasible option to 
protect against atherogenic inflammation.
In contrast, we demonstrate that JAM-A deficiency in 
BM-derived leukocytes aggravates atherosclerotic lesion for-
mation. Dendritic cells deficient in JAM-A display higher 
migratory capacity in lymphoid organs but not in blood ves-
sels,11 whereas JAM-A–deficient polymorphonuclear cells 
show reduced diapedesis in peritonitis and ischemia-reper-
fusion injury, related to impaired de-adhesion and polarized 
motility.12 We found that JAM-A–deficient monocytes indeed 
display defects in de-adhesion and complete transendothelial 
migration, likely a result of persistently increased activity of 
β2 integrins. Consequently, monocytes become entrapped 
Figure 5. Expression and localization of junctional adhesion molecule (JAM)-A under atherogenic conditions. A and B, Human aortic 
endothelial cells (HAoECs) were treated with or without low-density lipoprotein (LDL), oxidized low-density lipoprotein (oxLDL; 16 h), 
tumor necrosis factor (TNF)-α/interferon (IFN)-γ (4 h), or cycloheximide (Chex, 1 h), before incubation with fluorescent microbeads 
coupled to JAM-A antibodies (green). After washing, representative images were taken (A), and beads were counted (B) and normalized 
to the number of endothelial cells (blue). Scale bar, 40 µm. Counts were corrected for unspecific binding using beads carrying isotype 
control. C, HAoECs were treated with LDL (open symbols) or oxLDL (solid symbols) for 16 h at indicated concentrations. Quantitative 
real-time PCR normalized to GAPDH (left, n=3) and Western blot analyses normalized to Ponceau staining (right, n=5) were performed. 
D, Transendothelial migration of CD14+ monocytes across HAoECs treated with or without (open bar) LDL, TNF-α/IFN-γ, or oxLDL and 
with or without blocking JAM-A.Fc fusion protein (black bars) under flow conditions. Transmigrated cells were counted and normalized to 
the total number of adherent cells. Data represent mean±SEM of 3 independent experiments. P values were calculated by 1-way ANOVA 
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between the endothelial cell layer and the basement mem-
brane and may thereby cause vascular damage. Our data thus 
indicate that the presence of leukocytic JAM-A may limit ath-
erogenic damage by enabling physiological de-adhesion and 
migration of mononuclear cells.
No significant alterations of atherosclerotic lesion for-
mation were found in mice with somatic JAM-A deletion, 
pointing towards an intermediate phenotype between the 
atherogenic influence of endothelial JAM-A and the pro-
tective functions of leukocytic JAM-A. Notably, the reduc-
tion in Mac-2+ and CD3+ cell content in mice with either 
endothelial or leukocytic deficiency in JAM-A was not reca-
pitulated in JAM-A–/– mice, where no difference could be 
observed. This may be attributable to counteracting effects 
of JAM-A deficiency in cells other than endothelial and 
BM-derived cells (e.g. smooth muscle cells, pericytes, or 
non–BM-derived resident macrophages). The intermedi-
ate phenotype was also reflected in the classification of 
lesion stages. In general, irradiation for BM reconstitution 
appeared to accelerate the development of more advanced 
stage plaques, whereas the deficiency in endothelial JAM-A 
delayed lesion progression and clearly favored a retention in 
early lesion stages.
We used various assays to assess the capacity of JAM-A-
deficient leukocytes or endothelial cells to support recruitment 
in vivo, ex vivo and in vitro and we provide novel in vitro 
evidence that a deficiency in endothelial JAM-A might also 
allow for monocytes to reappear on the monolayer by pas-
sively permitting reverse migration, contributing to the overall 
decrease in complete transmigration. This retentive control 
exerted by JAM-A complements a reverse gate-keeper func-
tion revealed for JAM-C in a study in which blocking JAM-C 
reduced the number of monocytes in inflammatory tissue by 
increasing reverse transmigration.35 Accordingly, a hesitant or 
reverse transmigration behavior has been identified for neutro-
phils during inflammation after ischemia-reperfusion injury in 
vivo, which was characterized by lower expression of JAM-C 
at endothelial junctions, enhanced by blockade or genetic 
deletion of JAM-C36, and implicated in systemic dissemina-
tion of inflammation.
Mechanistically, the exacerbation of atherosclerotic lesion 
formation by endothelial JAM-A appears to be attributable to 
its redistribution from the intercellular junctions to the lumi-
nal surface, and to an upregulated expression under athero-
genic conditions, thus increasing the availability of luminal 
JAM-A. Previous work has addressed the redistribution of 
Figure 6. Expression and localization of junctional adhesion molecule (JAM)-A during altered flow conditions. A, Visualization of JAM-A 
(green), CD31 (red), and collagen (blue) in control (left) and treated carotid arteries (right) at the common part and the bifurcation, 2 
weeks after partial ligation. Images are total projections of z-stacks. Scale bar, 40 µm. B, Quantification of the percentage of junctions 
staining positive for both JAM-A and CD31 in controls and carotid arteries, 2 and 8 weeks after partial ligation (n=4–6). C and D, 
Expression of JAM-A mRNA relative to 18S housekeeper, as analyzed by qRT-PCR (C), and expression of JAM-A protein relative to 
CD31, as quantified by immunofluorescence (D) in human aortic endothelial cells (HAoECs) cultured under static or flow conditions, as 
indicated (n=19–32). E and F, Quantification of Oil-red-O+ lesion surface in areas of low/oscillatory shear flow (inner curvature), high/
laminar shear flow (outer curvature), or the total aortic arch (E), and number of plaques in the descending, abdominal and total aorta (F) 
of eJAM-A+/+Apoe–/– and eJAM-A–/–Apoe–/– mice fed a high-fat diet for 12 weeks (n=10–13). G and H, Expression of miR-145 relative to 
U44 housekeeper in HAoECs cultured under static or flow conditions (G) and expression of JAM-A mRNA relative to 18S housekeeper in 
HAoECs transfected with miR-145-3p, miR-145-5p mimics or control (H), as analyzed by qRT-PCR (n=3–4). Data represent mean±SEM, 
and P values were calculated by 1-way ANOVA with Tukey multiple comparison (B, E, F, and H), Kruskal-Wallis with Dunn’s post-test 
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endothelial JAM-A, showing that JAM-A is relocalized to the 
apical surface in a cytokine-dependent manner under static 
or flow conditions in vitro.15–17,34 We extend these findings by 
unveiling a focal upregulation and redistribution of JAM-A 
expression in endothelial cells of carotid arteries under ath-
erogenic conditions of hyperlipidemia. The increased luminal 
JAM-A availability could mediate enhanced recruitment and 
higher content of macrophages and T-cells in atherosclerotic 
plaques of hyperlipidemic mice. In vitro experiments con-
firmed that oxidized LDL increased expression of JAM-A and 
its redistribution to the apical surface.
Our data challenge the intuitive assumption that knocking-
out a protein that is crucially involved in junctional barrier 
function would cause a nonspecific influx of leukocytes. 
Rather, the evidence presented in this study refutes a role 
of JAM-A in limiting transendothelial migration and points 
towards a specific role of JAM-A in leukocyte recruitment 
in the context of atherosclerosis. First, genetic deficiency 
in endothelial JAM-A decreased infiltration of plaques with 
macrophages and T cells and reduced luminal monocyte 
extravasation in carotid arteries in vivo. Second, redistribu-
tion of JAM-A induced by oxLDL facilitated the transmigra-
tion of monocytes.
The increase in expression and focal redistribution of 
JAM-A in response to atherogenic stimulation with oxLDL 
reveals a striking similarity to JAM-C, a related JAM family 
member, which displays increased expression and redistribu-
tion to the apical surface after oxLDL treatment.37 Like for 
JAM-A, JAM-C predominantly localized to interendothelial 
contacts under quiescent conditions, oxLDL induced a disor-
ganized JAM-C localization that was no longer restricted to 
interendothelial junctions, and JAM-C supported both adhe-
sion and transmigration upon oxLDL stimulation.37
The upregulation and luminal redistribution of JAM-A is 
enhanced by aberrant shear flow conditions (e.g. after partial 
ligation or at predilection sites), whereas laminar shear flow 
appears to exert beneficial effects on JAM-A, limiting the 
susceptibility to atherogenesis. Accordingly, the reduction of 
atherosclerotic lesion formation in the aortic arch was more 
prominent in regions of low shear rather than high shear (e.g. 
the inner curvature of the arch and branching points of the 
descending aorta). Of note, Krüppel-like factor 2–transduced 
or shear stress–stimulated human endothelial cells have been 
found to be enriched in miR-143/145, providing a mechanism 
for atheroprotective communication with neighboring SMCs 
via miR-145-containing microvesicles.32 Our data confirmed 
that shear flow induces an increase in miR-145 expression 
in arterial endothelial cells, which is highly relevant and 
extends findings identifying JAM-A as a miR-145-target in 
tumor cells.38 The overexpression of miR-145 suppressed the 
expression of JAM-A in endothelial cells, which was mir-
rored by the flow-dependent reduction in JAM-A expression. 
Thus, miR-145 is a regulator of JAM-A in the setting of arte-
rial remodeling.
Notably, platelet endothelial adhesion molecule-1 
(PECAM-1), another Ig family adhesion molecule expressed 
on platelets, leukocytes, and endothelial cell junctions, has 
recently been found to regulate atherosclerotic plaque forma-
tion in a cell- and site-specific manner.39 In contrast to JAM-A, 
PECAM-1 on BM cells was proatherogenic irrespective of the 
hemodynamic environment, whereas PECAM-1, like JAM-A, 
reduced lesion formation in areas of disturbed flow but was 
atheroprotective in high shear regions by mechanisms yet to 
be elucidated.
In the context of arterial denudation injury, the neointi-
mal content of macrophages was reduced in mice with a 
somatic JAM-A deletion. This was likely attributable to a 
reduced JAM-A–dependent deposition of the chemokine 
CCL5 by platelets on the luminal surface of injured arter-
ies.20 Moreover, the phenotype of regenerating endothelial 
cells after wire-injury may differ, benefiting from increased 
JAM-A expression and its function in endothelial cell migra-
tion and shear resistance.40
Our study identifies the differential and cell type–specific 
contribution of JAM-A in atherosclerosis, namely a crucial 
involvement of endothelial JAM-A in atherogenic leukocyte 
recruitment in response to modified lipids and at predilection 
sites with disturbed flow. Increased expression and focal redis-
tribution of JAM-A controlled by miR-145 establish a novel 
set of mechanisms to explain the higher susceptibility to ath-
erosclerosis in regions with disturbed shear flow. Endothelial 
JAM-A may serve as a suitable marker for molecular imaging 
of early stages of lesion formation and may be developed as a 
therapeutic target to treat atherosclerosis.
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CLINICAL PERSPECTIVE
Atherosclerotic lesions develop in the larger arteries at sites of disturbed flow, but the mechanisms behind this observation 
still remain poorly defined. In this study, Schmitt and colleagues investigated the cell-specific roles of junctional adhesion 
molecule A (JAM-A) in a mouse model of atherosclerosis. Through the use of 2-photon laser scanning microscopy on intact 
mouse arteries, the authors discovered that under aberrant flow conditions and hyperlipidemia, the cellular localization of 
endothelial JAM-A changes from a defined junctional to a focal apical pattern, thereby facilitating the recruitment of mono-
cytes to the developing plaque. In vitro studies revealed that the expression of JAM-A was decreased by micro RNA 145, a 
micro RNA that is preferentially expressed under laminar flow conditions. These results highlight endothelial JAM-A as a 
proinflammatory factor that links aberrant flow conditions to inflammatory cell recruitment. These findings might be used to 
design novel and specific molecular imaging probes for the noninvasive detection of early endothelial dysfunction and for 
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